2-羟基醛,R f CH(R)CHO,其中R f = CF 3,C 2 F 5,n -C 3 F 7和R = CF 3,C 2 F 5,n -C 3 F 7,Ph, H,制备通过相应的乙烯基醚的酸水解,R ˚F C(R)= CHOCH 3,其可通过的反应容易地制备[博士3P+C¯霍奇3]与相应的酮。可以通过自由基卤化将2-氢醛化学选择性转化为酰基卤R f CH(R)C(O)X(X = Cl,Br)。全氟烷基使2-位失活,成为2-氢的自由基夺取基团,卤化仅发生在甲酰基氢上。但是,冰乙酸中的2-氢醛的卤代化学选择性地产生了2-卤醛,R f CX(CHO)CHO,X = Cl,Br。2-氢全氟酰基卤的水解提供了有用的途径来获得2-氢全氟烷基支链的羧酸,有用的乙烯酮前体。该途径避免了使用有毒的氟代烯烃,例如全氟异丁烯。
<i>N</i>-Ammonium Ylide Mediators for Electrochemical C–H Oxidation
作者:Masato Saito、Yu Kawamata、Michael Meanwell、Rafael Navratil、Debora Chiodi、Ethan Carlson、Pengfei Hu、Longrui Chen、Sagar Udyavara、Cian Kingston、Mayank Tanwar、Sameer Tyagi、Bruce P. McKillican、Moses G. Gichinga、Michael A. Schmidt、Martin D. Eastgate、Massimiliano Lamberto、Chi He、Tianhua Tang、Christian A. Malapit、Matthew S. Sigman、Shelley D. Minteer、Matthew Neurock、Phil S. Baran
DOI:10.1021/jacs.1c03780
日期:2021.5.26
taking a first-principles approach guided by computation, these new mediators were identified and rapidly expanded into a library using ubiquitous buildingblocks and trivial synthesis techniques. The ylide-based approach to C–H oxidation exhibits tunable selectivity that is often exclusive to this class of oxidants and can be applied to real-world problems in the agricultural and pharmaceutical sectors
[EN] HCV NS3 PROTEASE INHIBITORS<br/>[FR] INHIBITEURS DE LA PROTÉASE NS3 DU VHC
申请人:MERCK SHARP & DOHME
公开号:WO2014025736A1
公开(公告)日:2014-02-13
The present invention relates to hepatitis C virus (HCV) NS3 protease inhibitors containing a spirocyclic moeity, uses of such compounds, and synthesis of such compounds.
emergence of direct enolization protocols providing atom-economical and operationally simple methods to use enolates for stereoselective C-C bond-forming reactions, eliminating the inherent drawback of the preformation of enolates using stoichiometric amounts of reagents. In its infancy, direct enolization relied heavily on the intrinsic acidity of the latent enolates, and the reaction scope was limited
Compounds of formula (I) as described herein, processes for their production and their use as pharmaceuticals.
本文件所述的式(I)化合物、其制备方法以及作为药物的用途。
Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia
申请人:Palani Anandan
公开号:US20060264489A1
公开(公告)日:2006-11-23
A compound having the general structure of Formula (I):
or a pharmaceutically acceptable salt, solvate, ester, or tautomer thereof, wherein:
Q is selected from the group consisting of:
and
L is selected from the group consisting of:
or a pharmaceutically acceptable salt, solvate, ester, or tautomer thereof, are useful in treating diseases, disorders, or conditions such as metabolic syndrome and dyslipidemia.